€0.76
Your prediction
Financial data and news for Tempramed Technologies Ltd.
sharewise wants to provide you with the best news and tools for Tempramed Technologies Ltd., so we directly link to the best financial data sources.
Financials
News
TempraMed Launches New Product, VIVI Cap Smart, Expanding its Portfolio to Include a Digital Health Offering
Integrated smart technology builds on TempraMed’s proven VIVI platform, providing robust Temperature control with medication management for individuals using life-saving medication
Highlig
TempraMed Enters Strategic Media Partnership with Dr. Phil’s Envoy Media, Validating Product Portfolio and Accelerating Market Adoption Across the United States
Access to an audience of over 19 million individuals monthly will expand national exposure, and supports scalable demand generation across B2C and B2B channels for TempraMed’s full product
TempraMed Launches New Product “VIVI Med™, Unlocking New Growth Opportunities in High-Value Biologics and Injectable Medications
Using same proprietary, patented technology, VIVI Med extends the product portfolio beyond injectable pens, opening access to broader patient populations, premium biologics, and institutional
TempraMed Receives Positive Response on Payor Reimbursement Model Driving Significant Return on Investment for Medical Payor Coverage
Validation is expected to accelerate TempraMed’s path to payor reimbursement for product portfolio
Highlights
- ROI model validated for savings and metrics by Validation
TempraMed Closes C$2.5 Million Fully Subscribed Private Placement
Vancouver, BC – January 12, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical-technology innovator transforming how temperature-sensitive
TempraMed Receives First Commercial Order from Israel Distributor and Completes Initial Shipment Enabling Entry into National Pharmacy Network
Initial shipment delivered to distributor warehouse supports expansion into B2B pharmacy distribution alongside direct-to-consumer activities
Vancouver, BC - January 7, 2026 - TempraMed
TempraMed Provides Positive Recap on 2025 and Strategic Outlook for 2026
Vancouver, BC – January 2, 2026 – TempraMed Technologies Ltd. (CSE: VIVI) (FSE: 9DY) (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive
TempraMed Expands U.S. Manufacturing Capacity with New Production Facility in Florida
New facility increases output, reduces cost of goods sold (COGS) and enhances service for B2B customers to address the forecasted increased demand for products
Highlights:
-
TempraMed Strengthens Global Intellectual Property Position with Grant of South Korean Patent
Highlights
- Newly granted patent protects TempraMed’s VIVI Box™ proprietary, hassle-free thermal-insulation system and smart-monitoring architecture
- Expands the
TempraMed Appoints Leading Diabetes Researcher Professor Dr. Lutz Heinemann to its Scientific Advisory Board
A renowned expert in insulin pharmacology, diabetes technology, and temperature-sensitive medication stability joins TempraMed to strengthen scientific leadership.
Vancouver, BC – December
TempraMed Announces Strategic Agreement with Maccabi Healthcare Services, a Leading HMO with over 2.8 Million Patients
Vancouver, BC – December 8, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and
TempraMed Expands European Footprint with Distribution Partnership in Netherlands, Belgium, and Luxembourg
Vancouver, BC – December 5, 2025 – TempraMed Technologies Ltd. (“TempraMed” or the “Company”), a medical technology innovator transforming how temperature-sensitive medications are stored and
TempraMed Signs Exclusive Commercial Distribution Agreement with Leading Distributor to the Turkish Market
- Dolfin is a well-established, diversified distributor with broad reach across healthcare, hospitals, emergency services, and consumers provides strong potential for VIVI products
TempraMed Signs Exclusive Distribution Agreement with Leading Consumer Health Distributor in Israel
- Leading distributor of global companies including GSK/Haleon, Cargill, Reynolds, Paskesz
- Guri distributes reputable brands including Sensodyne, Aquafresh, Parodontax,